Jump to top menu Jump to main menu Jump to content
gender-neutraal-avatar
Researcher

M.J. Sonneveld

Gastroenterologist and Hepatologist

  • Department
  • Gastroenterology and Hepatology

About

Introduction

Milan Sonneveld is a staff Gastroenterologist & Hepatologist and Epidemiologist at the department of Gastroenterology & Hepatology of the Erasmus MC University Medical Center in Rotterdam, the Netherlands. He studied Medicine at the Erasmus University in Rotterdam and was trained as an epidemiologist at the Netherlands Insitute for Health Sciences (NIHES) and Harvard School of Public Health. He subsequently acquired a PhD for his thesis entitled ‘Host and Viral Predictors of Response to Antiviral Therapy in Chronic Hepatitis B’. After completing his Gastroenterology & Hepatology residencies at the Ikazia Hospital and the Erasmus MC University Medical Center he obtained a staff position at the Erasmus MC in 2021.

His research aims to facilitate personalized healthcare for patients with chronic hepatitis B through the study of individualized antiviral treatment strategies and identification of predictors of long-term adverse clinical outcomes. He is the principal investigator of several international research consortia and coordinator of the Dutch HBV management guideline (www.HBVRichtsnoer.nl).

Publications

Recent publications

  1. Sonneveld MJ, Hardeman S, Kuipers EJ, de Graaf W, Spaander MCW, van der Meer AJ. Effect of the COVID-19 pandemic on procedure volumes in gastroenterology in the Netherlands. Lancet Gastroenterol Hepatol 2022
  2. Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE Study Group. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). Clin Gastroenterol Hepatol. 2022 Apr;20(4):e784-e793.
  3. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B; CREATE study group. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J Hepatol. 2022 May;76(5):1042-1050.
  4. van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, Janssen HLA, de Knegt RJ, Sonneveld MJ. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021 Aug 8;3(5):100350.